I think the response will be much more nuanced because the letter is demanding a wholesale retraction of the Nader presentation that would seem to also require a lot of undermining of our understanding of the safety profile of Leronlimab. I think there may be a negotiated process with FDA of what the final response will be. Again I see SA being integral to this process.